Literature DB >> 27308535

The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors.

Luping Lin1, Trever G Bivona1.   

Abstract

RAF- and MEK-targeted therapies are approved for patients with BRAF(V600E) melanoma and under investigation in a several other tumor types, but resistance remains a major challenge. We uncovered yes-associated protein 1 (YAP1) as a mechanism of resistance to RAF-MEK inhibition in BRAF- and RAS-mutant cancers, providing a rationale for co-targeting YAP and RAF-MEK to enhance patient outcomes.

Entities:  

Keywords:  BRAF; Hippo; MEK; RAS; YAP; resistance; targeted therapy

Year:  2015        PMID： 27308535      PMCID： PMC4845171          DOI： 10.1080/23723556.2015.1021441

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  9 in total

1.  The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.

Authors:  Luping Lin; Amit J Sabnis; Elton Chan; Victor Olivas; Lindsay Cade; Evangelos Pazarentzos; Saurabh Asthana; Dana Neel; Jenny Jiacheng Yan; Xinyuan Lu; Luu Pham; Mingxue M Wang; Niki Karachaliou; Maria Gonzalez Cao; Jose Luis Manzano; Jose Luis Ramirez; Jose Miguel Sanchez Torres; Fiamma Buttitta; Charles M Rudin; Eric A Collisson; Alain Algazi; Eric Robinson; Iman Osman; Eva Muñoz-Couselo; Javier Cortes; Dennie T Frederick; Zachary A Cooper; Martin McMahon; Antonio Marchetti; Rafael Rosell; Keith T Flaherty; Jennifer A Wargo; Trever G Bivona
Journal:  Nat Genet       Date:  2015-02-09       Impact factor: 38.330

2.  Reliable and effective diagnostics are keys to accelerating personalized cancer medicine and transforming cancer care: a policy statement from the american association for cancer research.

Authors:  Charles L Sawyers; Laura J van 't Veer
Journal:  Clin Cancer Res       Date:  2014-09-09       Impact factor: 12.531

3.  Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP-TEAD Protein-Protein Interaction.

Authors:  Zhisen Zhang; Zhaohu Lin; Zheng Zhou; Hong C Shen; S Frank Yan; Alexander V Mayweg; Zhiheng Xu; Ning Qin; Jason C Wong; Zhenshan Zhang; Yiping Rong; David C Fry; Taishan Hu
Journal:  ACS Med Chem Lett       Date:  2014-07-14       Impact factor: 4.345

Review 4.  The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease.

Authors:  Xaralabos Varelas
Journal:  Development       Date:  2014-04       Impact factor: 6.868

Review 5.  The emerging roles of YAP and TAZ in cancer.

Authors:  Toshiro Moroishi; Carsten Gram Hansen; Kun-Liang Guan
Journal:  Nat Rev Cancer       Date:  2015-01-16       Impact factor: 60.716

6.  Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.

Authors:  Luping Lin; Saurabh Asthana; Elton Chan; Sourav Bandyopadhyay; Maria M Martins; Victor Olivas; Jenny Jiacheng Yan; Luu Pham; Mingxue Michelle Wang; Gideon Bollag; David B Solit; Eric A Collisson; Charles M Rudin; Barry S Taylor; Trever G Bivona
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-03       Impact factor: 11.205

Review 7.  Circumventing cancer drug resistance in the era of personalized medicine.

Authors:  Levi A Garraway; Pasi A Jänne
Journal:  Cancer Discov       Date:  2012-02-28       Impact factor: 39.397

Review 8.  Genetics and biomarkers in personalisation of lung cancer treatment.

Authors:  Rafael Rosell; Trever G Bivona; Niki Karachaliou
Journal:  Lancet       Date:  2013-08-24       Impact factor: 79.321

9.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Authors:  Gideon Bollag; Peter Hirth; James Tsai; Jiazhong Zhang; Prabha N Ibrahim; Hanna Cho; Wayne Spevak; Chao Zhang; Ying Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Garson Tsang; Brian L West; Ben Powell; Rafe Shellooe; Adhirai Marimuthu; Hoa Nguyen; Kam Y J Zhang; Dean R Artis; Joseph Schlessinger; Fei Su; Brian Higgins; Raman Iyer; Kurt D'Andrea; Astrid Koehler; Michael Stumm; Paul S Lin; Richard J Lee; Joseph Grippo; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Paul B Chapman; Keith T Flaherty; Xiaowei Xu; Katherine L Nathanson; Keith Nolop
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962
  9 in total
  10 in total

1.  The dynamic mechanism of RASSF5 and MST kinase activation by Ras.

Authors:  Tsung-Jen Liao; Hyunbum Jang; Chung-Jung Tsai; David Fushman; Ruth Nussinov
Journal:  Phys Chem Chem Phys       Date:  2017-03-01       Impact factor: 3.676

2.  The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer.

Authors:  Paula González-Alonso; Sandra Zazo; Ester Martín-Aparicio; Melani Luque; Cristina Chamizo; Marta Sanz-Álvarez; Pablo Minguez; Gonzalo Gómez-López; Ion Cristóbal; Cristina Caramés; Jesús García-Foncillas; Pilar Eroles; Ana Lluch; Oriol Arpí; Ana Rovira; Joan Albanell; Sander R Piersma; Connie R Jimenez; Juan Madoz-Gúrpide; Federico Rojo
Journal:  Cancers (Basel)       Date:  2020-04-29       Impact factor: 6.639

Review 3.  Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.

Authors:  Aubhishek Zaman; Trever G Bivona
Journal:  Ann Transl Med       Date:  2018-05

Review 4.  The Role of the Hippo Pathway in Breast Cancer Carcinogenesis, Prognosis, and Treatment: A Systematic Review.

Authors:  Anastasios Kyriazoglou; Michalis Liontos; Roubini Zakopoulou; Maria Kaparelou; Anna Tsiara; Alkistis Maria Papatheodoridi; Rebecca Georgakopoulou; Flora Zagouri
Journal:  Breast Care (Basel)       Date:  2020-05-12       Impact factor: 2.860

Review 5.  Cancer's Achilles' Heel: Apoptosis and Necroptosis to the Rescue.

Authors:  Atreyi Dasgupta; Motonari Nomura; Ryan Shuck; Jason Yustein
Journal:  Int J Mol Sci       Date:  2016-12-23       Impact factor: 5.923

6.  Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells.

Authors:  Matthew L Fisher; Daniel Grun; Gautam Adhikary; Wen Xu; Richard L Eckert
Journal:  Oncotarget       Date:  2017-11-22

7.  Gomesin inhibits melanoma growth by manipulating key signaling cascades that control cell death and proliferation.

Authors:  Maria P Ikonomopoulou; Manuel A Fernandez-Rojo; Sandy S Pineda; Pablo Cabezas-Sainz; Brit Winnen; Rodrigo A V Morales; Andreas Brust; Laura Sánchez; Paul F Alewood; Grant A Ramm; John J Miles; Glenn F King
Journal:  Sci Rep       Date:  2018-08-01       Impact factor: 4.379

8.  MEK Inhibition Induces Canonical WNT Signaling through YAP in KRAS Mutated HCT-15 Cells, and a Cancer Preventive FOXO3/FOXM1 Ratio in Combination with TNKS Inhibition.

Authors:  Nina Therese Solberg; Maria Melheim; Martin Frank Strand; Petter Angell Olsen; Stefan Krauss
Journal:  Cancers (Basel)       Date:  2019-02-01       Impact factor: 6.639

Review 9.  Targeting Oncogenic BRAF: Past, Present, and Future.

Authors:  Aubhishek Zaman; Wei Wu; Trever G Bivona
Journal:  Cancers (Basel)       Date:  2019-08-16       Impact factor: 6.639

10.  Yes-activated protein promotes primary resistance of BRAF V600E mutant metastatic colorectal cancer cells to mitogen-activated protein kinase pathway inhibitors.

Authors:  Meng Su; Lei Zhan; Yong Zhang; Jingdong Zhang
Journal:  J Gastrointest Oncol       Date:  2021-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.